Kelly Chibale
@kellychibale.bsky.social
Professor of Organic Chemistry and Neville Isdell Chair in African-centric drug discovery & development at University of Cape Town. Editor-In-Chief at ACS Medicinal Chemistry Letters
We must #StopAtNothing to defeat them. We must invest to finish the job.
www.theglobalfund.org/en/investmen...
www.theglobalfund.org/en/investmen...
Eighth Replenishment Investment Case
The Global Fund partnership has made remarkable progress in the fight against AIDS, tuberculosis (TB) and malaria over the last two decades – saving 70 million lives and reducing the combined death ra...
www.theglobalfund.org
November 17, 2025 at 5:41 AM
We must #StopAtNothing to defeat them. We must invest to finish the job.
www.theglobalfund.org/en/investmen...
www.theglobalfund.org/en/investmen...
#KellyChibale #AIinScience #Pharmacogenomics #MalariaResearch #TuberculosisResearch #PrecisionMedicine #AfricaScience #GlobalHealth #DrugDiscovery
November 11, 2025 at 7:51 AM
(5/5) Despite being the most genetically diverse continent, Africa’s unique pharmacogenetic profiles remain underrepresented in global research. Our work helps to bridge that gap. Read the full open-access article here: www.nature.com/articles/s41...
Artificial intelligence coupled to pharmacometrics modelling to tailor malaria and tuberculosis treatment in Africa - Nature Communications
Authors analyzed malaria and tuberculosis drugs to create a pharmacometric model. They used an AI pipeline that prioritized pharmacogenetic drug-gene pairs with an emphasis on high variant frequency g...
www.nature.com
November 11, 2025 at 7:51 AM
(5/5) Despite being the most genetically diverse continent, Africa’s unique pharmacogenetic profiles remain underrepresented in global research. Our work helps to bridge that gap. Read the full open-access article here: www.nature.com/articles/s41...
(4/5) The significance of this work? Differences in how individuals and populations respond to medicines often arise from genetic variation in drug-metabolising enzymes and transporters – key factors influencing safety and efficacy.
Artificial intelligence coupled to pharmacometrics modelling to tailor malaria and tuberculosis treatment in Africa - Nature Communications
Authors analyzed malaria and tuberculosis drugs to create a pharmacometric model. They used an AI pipeline that prioritized pharmacogenetic drug-gene pairs with an emphasis on high variant frequency g...
www.nature.com
November 11, 2025 at 7:51 AM
(4/5) The significance of this work? Differences in how individuals and populations respond to medicines often arise from genetic variation in drug-metabolising enzymes and transporters – key factors influencing safety and efficacy.
(3/5) By focusing on #malaria and #tuberculosis – two major diseases on the African continent, yet both understudied pharmacogenetically – we aim to improve treatment outcomes and advance precision medicine for the continent.
Artificial intelligence coupled to pharmacometrics modelling to tailor malaria and tuberculosis treatment in Africa - Nature Communications
Authors analyzed malaria and tuberculosis drugs to create a pharmacometric model. They used an AI pipeline that prioritized pharmacogenetic drug-gene pairs with an emphasis on high variant frequency g...
www.nature.com
November 11, 2025 at 7:51 AM
(3/5) By focusing on #malaria and #tuberculosis – two major diseases on the African continent, yet both understudied pharmacogenetically – we aim to improve treatment outcomes and advance precision medicine for the continent.
(2/3) Here, we introduce an #AI-driven pipeline combining machine learning, pharmacometrics modelling to uncover drug-gene pairs of pharmacogenetic interest and propose dose adjustments tailored to African populations.
Artificial intelligence coupled to pharmacometrics modelling to tailor malaria and tuberculosis treatment in Africa - Nature Communications
Authors analyzed malaria and tuberculosis drugs to create a pharmacometric model. They used an AI pipeline that prioritized pharmacogenetic drug-gene pairs with an emphasis on high variant frequency g...
www.nature.com
November 11, 2025 at 7:51 AM
(2/3) Here, we introduce an #AI-driven pipeline combining machine learning, pharmacometrics modelling to uncover drug-gene pairs of pharmacogenetic interest and propose dose adjustments tailored to African populations.
(4/4) Read our full Comment in @Nature: www.nature.com/articles/d41...
#KellyChibale #AfricanMedicinesAgency #PublicHealth #ClinicalResearch #DrugDiscovery #GlobalHealth #AfricaScience #Pharmacogenomics
#KellyChibale #AfricanMedicinesAgency #PublicHealth #ClinicalResearch #DrugDiscovery #GlobalHealth #AfricaScience #Pharmacogenomics
Africa finally has its own drug-regulation agency — and it could transform the continent’s health
If it gets things right, the first major regulator of medicines to launch for 30 years could empower Africa to tackle African challenges around health and disease.
www.nature.com
November 11, 2025 at 7:32 AM
(4/4) Read our full Comment in @Nature: www.nature.com/articles/d41...
#KellyChibale #AfricanMedicinesAgency #PublicHealth #ClinicalResearch #DrugDiscovery #GlobalHealth #AfricaScience #Pharmacogenomics
#KellyChibale #AfricanMedicinesAgency #PublicHealth #ClinicalResearch #DrugDiscovery #GlobalHealth #AfricaScience #Pharmacogenomics
(3/4) The AMA seeks to embed African data into global drug discovery. By harmonising regulations, boosting local trials and promoting Africa-led pharmacogenomics and biobanking, the AMA can help to ensure that treatments are safe, effective and equitable for all people of African ancestry.
Africa finally has its own drug-regulation agency — and it could transform the continent’s health
If it gets things right, the first major regulator of medicines to launch for 30 years could empower Africa to tackle African challenges around health and disease.
www.nature.com
November 11, 2025 at 7:32 AM
(3/4) The AMA seeks to embed African data into global drug discovery. By harmonising regulations, boosting local trials and promoting Africa-led pharmacogenomics and biobanking, the AMA can help to ensure that treatments are safe, effective and equitable for all people of African ancestry.
(2/4) Africa holds the world’s greatest genetic diversity, yet less than 3% of global clinical trials occur here. Too often, drugs and vaccines are designed, tested and approved elsewhere – making some treatments ineffective or even harmful for Africans.
Africa finally has its own drug-regulation agency — and it could transform the continent’s health
If it gets things right, the first major regulator of medicines to launch for 30 years could empower Africa to tackle African challenges around health and disease.
www.nature.com
November 11, 2025 at 7:32 AM
(2/4) Africa holds the world’s greatest genetic diversity, yet less than 3% of global clinical trials occur here. Too often, drugs and vaccines are designed, tested and approved elsewhere – making some treatments ineffective or even harmful for Africans.